Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial

Study Identifier
MA-SXR-09-005
CT.gov Identifier
NCT01178827
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Bladder Disorder - Overactive Bladder
    • Study Drug
  • trospium chloride
  • oxybutynin IR
  • oxybutynin IR placebo
    • Phase
    Phase 4
    Sex
    Female & Male
    Age
    60+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Patient presents symptoms of overactive bladder * Patient has age associated memory impairment * No acute or unstable medical conditions
    Exclusion Criteria:
    * History of alcohol or substance abuse within 1 year prior to study * Has donated in excess of 500mL of blood or plasma in the 30 days prior to study * Has known bleeding disorder (hemophilia) * Previous abdominal bypass surgery for obesity

    Protocol Summary

    This study will evaluate the cerebrospinal fluid levels of trospium chloride (Sanctura XR®) and oxybutynin immediate release (Oxybutynin IR) on memory performance in patients with overactive bladder and age associated memory impairment.

    Study Locations

    Location
    Status
    Location
    Salt Lake City, Utah, United States
    Status
    Not applicable